113.08
1.56%
1.74
전일 마감가:
$111.34
열려 있는:
$110.76
하루 거래량:
863.98K
Relative Volume:
1.05
시가총액:
$27.11B
수익:
$3.30B
순이익/손실:
$-501.07M
주가수익비율:
9.8003
EPS:
11.5384
순현금흐름:
$1.03B
1주 성능:
-6.06%
1개월 성능:
+10.71%
6개월 성능:
+31.67%
1년 성능:
+10.00%
바이오앤테크 Stock (BNTX) Company Profile
BNTX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
바이오앤테크 Stock (BNTX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-12-11 | 개시 | Wells Fargo | Overweight |
2024-12-02 | 재확인 | BMO Capital Markets | Outperform |
2024-11-19 | 개시 | Berenberg | Buy |
2024-11-19 | 업그레이드 | Evercore ISI | In-line → Outperform |
2024-11-08 | 업그레이드 | Goldman | Neutral → Buy |
2024-09-24 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2024-09-17 | 업그레이드 | Jefferies | Hold → Buy |
2024-09-16 | 업그레이드 | JP Morgan | Underweight → Neutral |
2024-08-07 | 업그레이드 | Deutsche Bank | Hold → Buy |
2024-08-02 | 업그레이드 | HSBC Securities | Hold → Buy |
2024-05-14 | 개시 | Evercore ISI | In-line |
2024-02-23 | 개시 | BMO Capital Markets | Outperform |
2024-01-05 | 개시 | Oppenheimer | Perform |
2023-12-01 | 다운그레이드 | JP Morgan | Neutral → Underweight |
2023-10-16 | 다운그레이드 | HSBC Securities | Buy → Hold |
2023-07-14 | 개시 | HSBC Securities | Buy |
2023-05-17 | 업그레이드 | Redburn | Neutral → Buy |
2022-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
2022-08-17 | 개시 | Cowen | Market Perform |
2022-07-13 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
2022-07-06 | 재개 | Canaccord Genuity | Buy |
2022-02-01 | 업그레이드 | Redburn | Sell → Neutral |
2021-12-16 | 개시 | Morgan Stanley | Equal-Weight |
2021-11-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
2021-10-22 | 개시 | Deutsche Bank | Hold |
2021-10-07 | 개시 | Jefferies | Hold |
2021-08-11 | 업그레이드 | Bryan Garnier | Neutral → Buy |
2021-07-19 | 재개 | Wolfe Research | Outperform |
2021-06-16 | 다운그레이드 | Redburn | Neutral → Sell |
2021-05-18 | 개시 | Goldman | Neutral |
2021-05-11 | 다운그레이드 | Bryan Garnier | Buy → Neutral |
2020-12-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
2020-08-03 | 재개 | Berenberg | Buy |
2020-07-21 | 업그레이드 | BofA Securities | Neutral → Buy |
2020-06-30 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
2020-05-19 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
2020-04-28 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
2020-03-18 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2020-03-09 | 개시 | H.C. Wainwright | Neutral |
2020-01-24 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
2020-01-22 | 다운그레이드 | UBS | Buy → Neutral |
2019-11-05 | 개시 | Wolfe Research | Outperform |
2019-11-04 | 개시 | Berenberg | Buy |
2019-11-04 | 개시 | BofA/Merrill | Buy |
2019-11-04 | 개시 | Canaccord Genuity | Buy |
2019-11-04 | 개시 | JP Morgan | Overweight |
2019-11-04 | 개시 | SVB Leerink | Outperform |
2019-11-04 | 개시 | UBS | Buy |
모두보기
바이오앤테크 주식(BNTX)의 최신 뉴스
BioNTech SE ADR falls Thursday, underperforms market - MarketWatch
BioNTech SE ADR falls Wednesday, underperforms market - MarketWatch
3 No-Brainer Biotech Stocks to Buy With $200 Right Now - The Motley Fool
Stocks Generating Improved Relative Strength: BioNTech ADR - Investor's Business Daily
BioNTech SE ADR rises Tuesday, outperforms market - MarketWatch
BioNTech SE ADR falls Monday, underperforms market - MarketWatch
BioNTech's SWOT analysis: mRNA pioneer's stock faces oncology pipeline test - Investing.com
BioNTech SE ADR falls Friday, underperforms market - MarketWatch
BioNTech SE ADR rises Thursday, outperforms market - MarketWatch
BioNTech SE ADR rises Wednesday, outperforms market - MarketWatch
BioNTech SE ADR falls Tuesday, underperforms market - MarketWatch
BioNTech SE ADR rises Friday, outperforms market - MarketWatch
BioNTech's SWOT analysis: mRNA pioneer's stock balances COVID legacy, oncology future - Investing.com
BioNTech SE ADR rises Monday, outperforms market - MarketWatch
Stocks Showing Improving Market Leadership: BioNTech ADR Earns 81 RS Rating - Investor's Business Daily
BioNTech ADR Earns Relative Strength Rating Upgrade - Investor's Business Daily
BioNTech's SWOT analysis: oncology pipeline fuels stock's potential amid market volatility - Investing.com
BioNTech Stock Got A IBD RS Rating Lift - MSN
BioNTech ADR Shows Improved Relative Strength; Still Shy Of Benchmark - Inkl
Analysts Turn Bullish on BioNTech Stock Amid Volatility - Schaeffers Research
10 Biggest Biotechnology Companies - Investopedia
BioNTech SE ADR (BNTX): An Important Analyst Insights - Stocks Register
Powell Speaks The Truth - Benzinga
Goodwin, Conyers, A&O Shearman Act on $800M China Biotech Sale - Law.com International
BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock Up - Yahoo Finance
Stock Futures Quiet as Market Heads for Winning Week - Schaeffers Research
BioNTech Earnings: Strong Covid Revenue, but Full-Year Expectations Unchanged - Morningstar
BioNTech SE Reports Strong Q3 2024 Results - TipRanks
This 6%-yielding U.S. pharma giant is a safe hold - The Globe and Mail
Weekly Upgrades and Downgrades - InvestorPlace
BioNTech SE ADR outperforms market despite losses on the day - MarketWatch
Pfizer's Q3 Earnings Beat, Paxlovid Drives Sales Guidance Increase - Yahoo Finance
Will Non-COVID Drugs Again Boost Pfizer's Top Line in Q3 Earnings? - Nasdaq
BioNTech to Report Q3 Earnings: Is a Beat in the Cards? - MSN
바이오앤테크 (BNTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):